AGP Executive Report
Last update: 11 hours agoPrivacy Tools Tested: Incogni’s data-removal service is under the spotlight, with a fresh review asking whether the broker-hunting tool really works in practice. Cancer Care in Europe: The EU’s CHMP has issued a positive opinion for pembrolizumab plus enfortumab vedotin as perioperative and then after-surgery treatment for cisplatin-ineligible resectable muscle-invasive bladder cancer—next step is an EU Commission decision expected in Q3 2026. Rare Disease Breakthrough: Pharming’s Joenja (leniolisib) has received EU marketing authorization for activated PI3K delta syndrome (APDS), with first European launch expected in Germany in Q3 2026. Cross-Border Rules: UK travel warnings are back in focus: bringing meat or dairy from the EU can trigger fines up to £5,000 and confiscation. Local Relevance for Liechtenstein: Several of these approvals explicitly include Liechtenstein in the EU/EEA rollout plans, while the week also featured a Liechtenstein-linked kidney-transplant deal and broader European policy debates.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab/Enfortumab Vedotin in Cisplatin-Ineligible MIBC]]>](https://cdn.sanity.io/images/0vv8moc6/onclive/c32607911ff8c2b81ea841493078c23b4f97815c-1280x720.jpg)
